

APPLIED GENETIC TECHNOLOGIES CORP

Form 3

March 26, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person

\*  
^ MedImmune Ventures, Inc.

(Last) (First) (Middle)

ONE MEDIMMUNE WAY

(Street)

GAITHERSBURG,^ MD^ 20878

(City) (State) (Zip)

2. Date of Event  
Requiring Statement  
(Month/Day/Year)  
03/26/20143. Issuer Name **and** Ticker or Trading SymbolAPPLIED GENETIC TECHNOLOGIES CORP  
[AGTC]4. Relationship of Reporting  
Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_X\_\_ 10%  
Owner\_\_\_\_ Officer \_\_\_\_ Other  
(give title below) (specify below)5. If Amendment, Date Original  
Filed(Month/Day/Year)6. Individual or Joint/Group  
Filing(Check Applicable Line)  
\_\_X\_\_ Form filed by One Reporting  
Person  
\_\_\_\_ Form filed by More than One  
Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security  
(Instr. 4)2. Amount of Securities  
Beneficially Owned  
(Instr. 4)3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security  
(Instr. 4)2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)Date Expiration  
Exercisable Date3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)Title Amount or  
Number of  
Shares4. Conversion  
or Exercise  
Price of  
Derivative  
Security5. Ownership  
Form of  
Derivative  
Security:  
Direct (D)  
or Indirect  
(I)6. Nature of Indirect  
Beneficial  
Ownership  
(Instr. 5)

(Instr. 5)

Series A-1A Convertible Preferred Stock	Â <u>(1)</u>	Â <u>(1)</u>	Common Stock	690,678	\$ <u>(1)</u>	D	Â
Series B-1 Convertible Preferred Stock	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	183,126	\$ <u>(2)</u>	D	Â
Series B-2 Convertible Preferred Stock	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	339,826	\$ <u>(2)</u>	D	Â
Series B-3 Convertible Preferred Stock	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	162,831	\$ <u>(2)</u>	D	Â
Series B-1 Warrant (Right to Buy)	Â <u>(3)</u>	05/02/2017	Series B-1 Preferred Stock	416,361 <u>(2)</u>	\$ 0.1297	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MedImmune Ventures, Inc. ONE MEDIMMUNE WAY GAITHERSBURG, MD 20878	Â	Â X	Â	Â

## Signatures

/s/ Hemmie Chang, attorney-in-fact for MedImmune Ventures, Inc.

03/26/2014

    Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Each share of Series A-1 convertible preferred stock is convertible into shares of common stock at any time at the holder's election or upon consummation of a qualified public offering of the registrant on an approximately 1-for-16.62 basis. The Series A-1 convertible preferred stock has no expiration date.

(2) Each share of Series B-1, B-2 and B3 convertible preferred stock is convertible into shares of common stock at any time at the holder's election or upon the consummation of a qualified public offering of the registrant on a 1-for-35 basis. The Series B-1, B-2 and B-3 convertible preferred stock has no expiration date.

(3) The Series B-1 Warrant is exercisable for shares of Series B-1 convertible preferred stock at any time until the expiration of the warrant at the holder's election.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.